Beyond Cholesterol in the Primary Prevention of Cardiovascular Disease: Is The Polypill the Answer?
- First Online:
- 58 Downloads
In spite of major advances in the diagnosis and treatment of cardiovascular diseases, they remain the primary cause of death worldwide. Furthermore, the burden of disease is increasing steadily, particularly in emerging countries. Inappropriate prescription, unaffordable cost of medication, and lack of adherence to treatment all contribute to the failure of cardiovascular prevention. In addition, identification of patients at high risk of new ischemic events by means of the available scores is relatively inefficient, as most events occur in individuals with only modest elevations of risk factors. The concept of a fixed-dose combination or “polypill” has emerged recently as a potential strategy for improving cardiovascular disease burden. It is argued that such an approach will make unnecessary patient identification while reducing cost and improving adherence to medication. Several polypills are being developed and some of them are undergoing clinical testing.
KeywordsPolypill Cardiovascular prevention Primary prevention Statins
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.CrossRefPubMedGoogle Scholar
- 4.Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njølstad I, Oganov R, Thomsen T, Tverdal A, Wedel H, Wilhelmsen L, Graham I; SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16(5):541–9.CrossRefPubMedGoogle Scholar
- 8.Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–54.CrossRefPubMedGoogle Scholar
- 10.WHO report. Preventing chronic disease. Available at http://www.who.int/chp/chronic_disease_report Accessed September 2010
- 12.•• Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929–40. This third European survey provides a clear view of secondary prevention in 22 countries in Europe. CrossRefPubMedGoogle Scholar
- 13.Mendis S. WHO Study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bulletin of WHO 2005;83:820–8.Google Scholar
- 15.Pharma 2020: the vision. Which path will you take? Available at http://www.pwc.com/pharma. Accessed September 2010.
- 16.Bosworth HB. Medication treatment adherence. Chapter 6, 147–94. In: Bosworth H, Oddone, E., Weinberger, M., ed. In: “Patient treatment adherence”. Mahwah, New Jersey 2006.Google Scholar
- 18.• Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence. Its importance in cardiovascular outcomes. Circulation. 2009; 119:3028–3035 These authors summarize the present evidence on the importance of treatment adherence in the outcome of patients with chronic cardiac conditions. CrossRefPubMedGoogle Scholar
- 19.Jansà M, Hernández C, Vidal M, Nuñez M, Bertran MJ, Sanz S, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns. 2010 Feb 16Google Scholar
- 22.• Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart. 2010;96(8):604–9. The MITRA registry is an important piece of information regarding the role of secondary prevention in post-MI patients. CrossRefPubMedGoogle Scholar
- 28.UMPIRE. Use of a mltidrug pill in reducing cardiovascular events. Available at http://clinicaltrials.gov. Accessed September 2010
- 38.•• Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341–51. Epub 2009 Mar 30. This is the first large study analyzing the polypill in the clinical arena.CrossRefPubMedGoogle Scholar
- 39.Patel A, Shah T, Shah G, Jha V, Ghosh C, Desai J, Khamar B, Chakraborty BS. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. Am J Cardiovasc Drugs. 2010;10(2):95–103CrossRefPubMedGoogle Scholar
- 43.Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, Rastegarpanah M, Khoshnia M, Semnani S, Salahi R, Thomas GN, Larijani B, Cheng KK, Malekzadeh R. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010 Aug;64(9):1220–7.CrossRefPubMedGoogle Scholar